ReviewClinical cancer research : an official journal of the American Association for Cancer Research2014
Immunotherapy for brain cancer: recent progress and future promise.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 95 citations in OpenAlex.
- Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4CNS oncology · 2018Trial
- Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.Cancer immunology, immunotherapy : CII · 2016Trial
- Article
- Co-delivering macrophage engager mRNA and PD-L1 antibody via tumor-responsive nanoparticles for glioblastoma immunotherapy.Nature communications · 2026Article
- From Data to Decision: Integrating Bioinformatics into Glioma Patient Stratification and Immunotherapy Selection.International journal of molecular sciences · 2026Review
- Cognitive Decline in Glioblastoma (GB) Patients with Different Treatment Modalities and Insights on Untreated Cases.Current oncology (Toronto, Ont.) · 2025Review
- Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions.Journal of immunotherapy and precision oncology · 2024Article
- Advances in Glioblastoma Therapy: An Update on Current Approaches.Brain sciences · 2023Review
- Review
- Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma.Cell communication and signaling : CCS · 2023Review
- Targeting Glioblastoma-Associated Macrophages for Photodynamic Therapy Using AGuIXPharmaceutics · 2023Article
- Synthetic biology-inspired cell engineering in diagnosis, treatment, and drug development.Signal transduction and targeted therapy · 2023Review
- Review
- Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.Molecules (Basel, Switzerland) · 2023Review
- Immunotherapy: a promising approach for glioma treatment.Frontiers in immunology · 2023Review
- γδ T cells as a potential therapeutic agent for glioblastoma.Frontiers in immunology · 2023Review
- Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives.Military Medical Research · 2022Review
- Emerging therapies for glioblastoma: current state and future directions.Journal of experimental & clinical cancer research : CR · 2022Review
- Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Immunotherapy is emerging as the newest pillar of cancer treatment, with the potential to assume a place alongside surgical debulking, radiotherapy, and chemotherapy. Early experiences with antitumor vaccines demonstrated the feasibility and potential efficacy of this approach, and newer agents, such as immune checkpoint blocking antibodies and modern vaccine platforms, have ushered in a new era. These efforts are headlined by work in melanoma, prostate cancer, and renal cell carcinoma; however, substantial progress has been achieved in a variety of other cancers, including high-grade gliomas. A recurrent theme of this work is that immunotherapy is not a one-size-fits-all solution. Rather, dynamic, tumor-specific interactions within the tumor microenvironment continually shape the immunologic balance between tumor elimination and escape. High-grade gliomas are a particularly fascinating example. These aggressive, universally fatal tumors are highly resistant to radiotherapy and chemotherapy and inevitably recur after surgical resection. Located in the immune-privileged central nervous system, high-grade gliomas also use an array of defenses that serve as direct impediments to immune attack. Despite these challenges, vaccines have shown activity against high-grade gliomas, and anecdotal, preclinical, and early clinical data bolster the notion that durable remission is possible with immunotherapy. Realizing this potential, however, will require an approach tailored to the unique aspects of glioma biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.